Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 14;16(1):32.
doi: 10.1186/1532-429X-16-32.

Myocardial fibrosis in Eisenmenger syndrome: a descriptive cohort study exploring associations of late gadolinium enhancement with clinical status and survival

Craig S Broberg  1 , Sanjay K Prasad, Chad Carr, Sonya V Babu-Narayan, Konstantinos Dimopoulos, Michael A Gatzoulis
Affiliations

Myocardial fibrosis in Eisenmenger syndrome: a descriptive cohort study exploring associations of late gadolinium enhancement with clinical status and survival

Craig S Broberg et al. J Cardiovasc Magn Reson. .

Abstract

Background: A relationship between myocardial fibrosis and ventricular dysfunction has been demonstrated using late gadolinium enhancement (LGE) in the pressure-loaded right ventricle from congenital heart defects. In patients with Eisenmenger syndrome (ES), the presence of LGE has not been investigated. The aims of this study were to detect any myocardial fibrosis in ES and describe major clinical variables associated with the finding.

Methods: From 45 subjects screened, 30 subjects (age 43 ± 13 years, 20 female) underwent prospective cardiovascular magnetic resonance with LGE to quantify biventricular volume and function as well as maximal and submaximal exercise during a single visit. Standard cine acquisitions were obtained for ventricular volume and function. Further imaging was performed after administration of 0.1 mmol/kg gadolinium contrast. Regions of LGE were evaluated qualitatively and quantitatively by manual contouring of identified areas, with total area expressed as a percentage of mass. Patients were followed prospectively (mean follow up 7.4 ± 0.4 years) and any deaths recorded. Patients with LGE findings were compared to those without.

Results: LGE was present in 22/30 (73%) patients, specifically in RV myocardium (70%), RV trabeculae (60%), LV myocardium (33%) or LV papillary muscles (30%), though in small amounts (mean 1.4% of total ventricular mass, range 0.16 - 6.0%). Those with any LGE were not different in age, history of arrhythmia, desaturation, nor hemoglobin, nor ventricular size, mass, or function. Exercise capacity was low, but also not different between those with and without LGE. Similarly no significant associations were found with amount of fibrosis. There were five deaths among patients with LGE, versus two in patients without, but no difference in survival (log rank =0.03, P = 0.85).

Conclusions: Myocardial fibrosis by LGE is common in ES, though not extensive. The presence and quantity of LGE did not correlate with ventricular size, function, degree of cyanosis, exercise capacity, or survival in this pilot study. More data are clearly required before recommendations for routine use of LGE in these patients can be made.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Examples of late gadolinium enhancement of a papillary muscle showing and discrete plaque in the right ventricular free wall and inferior interventricular junction.
Figure 2
Figure 2
Late gadolinium enhancement in the right ventricular free wall as well as the RV-LV junction, which was not considered pathologic.
Figure 3
Figure 3
Scatterplots showing the relationship between right and left ventricular ejection fraction (Panel A, left) and mass (Panel B, right). Solid line is the linear trendline. Dotted line is the line of identity.
Figure 4
Figure 4
Kaplan Meier curve showing survival in patients with versus without late gadolinium enhancement in the subendocardium. There was no significant survival difference between the groups.
See this image and copyright information in PMC

References

    1. Diller GP, Dimopoulos K, Broberg CS, Kaya MG, Naghotra US, Uebing A, Harries C, Goktekin O, Gibbs JS, Gatzoulis MA. Presentation, survival prospects, and predictors of death in ES: a combined retrospective and case–control study. Eur Heart J. 2006;27:1737–42. doi: 10.1093/eurheartj/ehl116. Epub 2006 Jun 1722. - DOI - PubMed
    1. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–24. doi: 10.1016/j.jacc.2009.04.094. - DOI - PubMed
    1. Babu-Narayan SV, Goktekin O, Moon JC, Broberg CS, Pantely GA, Pennell DJ, Gatzoulis MA, Kilner PJ. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation. 2005;111:2091–8. doi: 10.1161/01.CIR.0000162463.61626.3B. - DOI - PubMed
    1. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, Khan M, Ho SY, Pennell DJ, Gatzoulis MA. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006;113:405–13. doi: 10.1161/CIRCULATIONAHA.105.548727. - DOI - PubMed
    1. Rathod RH, Prakash A, Powell AJ, Geva T. Myocardial fibrosis identified by cardiac magnetic resonance late gadolinium enhancement is associated with adverse ventricular mechanics and ventricular tachycardia late after Fontan operation. J Am Coll Cardiol. 2010;55:1721–8. doi: 10.1016/j.jacc.2009.12.036. - DOI - PMC - PubMed

Publication types

MeSH terms